were used to determine if these and other reported nonsense variants in PHOX2B exon 1 produced N-terminally truncated proteins. We found that all tested nonsense variants in PHOX2B exon 1 produced a truncated protein of the same size. This truncated protein localized to the nucleus and transactivated a target promoter. These data suggest that nonsense pathogenic variants in the first exon of PHOX2B likely escape nonsense mediated decay (NMD) and produce N-terminally truncated proteins functionally distinct from those produced by the more common PARMs.
CCHS is classified as a neurocristopathy, a diverse group of conditions arising from defects in the migration, division and differentiation of neural crest cells which leads to autonomic nervous system dysfunction (ANSD) (Bolande, 1997) . Patients with CCHS can have additional manifestations of ANSD including abnormalities of temperature regulation, sweating, blood pressure, and cardiac rhythm (Gronli, Santucci, Leurgans, Berry-Kravis, & Weese-Mayer, 2008; Rand et al., 2014; Saiyed et al., 2016) . Infants with CCHS are at risk for abnormalities in organs of neural crest origin, such as altered gut motility or Hirschsprung disease (HSCR) and peripheral neuroblastic tumors (PNTs): Extracranial tumors of neural crest origin including neuroblastomas, ganglioneuromas, and ganglioneuroblastomas (Weese-Mayer et al., 2010) .
More than 90% of CCHS causing pathogenic variants are located in a polyalanine repeat region in the third exon of PHOX2B. PHOX2B encodes a highly conserved homeobox domain transcription factor expressed in the peripheral and central autonomic nervous systems during embryonic development. PHOX2B is critical for the development of autonomic neural crest cell derivatives and controls hindbrain motor neuron development (Pattyn, Morin, Cremer, Goridis, & Brunet, 1999; Pattyn, Hirsch, Goridis, & Brunet, 2000) . Unaffected individuals have 20 alanines or fewer (Amiel et al., 2003; Weese-Mayer et al., 2010) . In contrast, those heterozygous for 24 or 25 repeats (e.g., genotype 20/24) can have a mild phenotype only manifesting during illness or exposure to respiratory depressants, (Repetto et al., 2009) , and those heterozygous for 26-33 alanine repeats are fully affected (Weese-Mayer et al., 2003 , 2010 .
Non-polyalanine repeat pathogenic variants (NPARMs) have been reported in fewer than 100 patients (Weese-Mayer et al., 2010) . A majority of these pathogenic variants are frameshifts in PHOX2B exon 3, affect the polyalanine repeat region, and result in a severe phenotype with extensive gut involvement, increased risk of peripheral neuroblastic tumors, cardiac arrhythmia, and need for continuous ventilator support (CVS) (Trochet et al., 2005; Weese-Mayer et al., 2010) . However, frameshift variants in the 3′ region of exon 2 and the 5′ region of exon 3 are associated with a milder form of CCHS that is variably penetrant (Berry-Kravis, Zhou, Rand, & Weese-Mayer, 2006; Bygarski et al., 2013; Low et al., 2014) . It has been postulated that frameshift variants in this region result in a phenotype similar to smaller polyalanine repeat expansions and are more likely to result in incomplete penetrance or adult-onset disease (Berry-Kravis et al., 2006; Weese-Mayer et al., 2010) .
Missense pathogenic variants primarily affect the homeo-domain of the protein and have a variable clinical presentation from only PNTs to PNTs plus CCHS and HSCR (Trochet et al., 2005 (Trochet et al., , 2009 Weese-Mayer et al., 2010) . Pathogenic variants primarily arise de novo, although inheritance from unaffected parents with incomplete penetrance or germline mosaicism has been reported (Parodi et al., 2008; Trochet et al., 2008) .
To our knowledge, four nonsense pathogenic variants in PHOX2B have been reported. A c.463A > T (p.Lys155*) variant in exon 3 was reported in a patient with CCHS, HSCR, and neuroblastoma (WeeseMayer et al., 2003) . In vitro studies showed that the p.Lys155* variant produces a stable, C-terminally truncated protein that does not appropriately localize to the nucleus and is unable to transactivate the dopamine-β-hydroxylate (DBH) and PHOX2A promoters (Trochet et al., 2009) . Three nonsense pathogenic variants have been reported in exon 1: c.18T > C (p.Tyr6*), c.23delA (p.Tyr8*) and c.42C > A (p. Tyr14*) (Magalhaes et al., 2015; Parodi et al., 2008; Trochet et al., 2009 ). Detailed clinical information was not available for the patient with the p.Tyr6* variant. Magalhaes et. al. (2015) reported a de novo p. Tyr8* variant in a patient who presented at 9, 11, and 13 months of age with severe respiratory failure during viral infections. Once the diagnosis of CCHS was made, bilevel positive airway pressure (BiPAP) non-invasive ventilation was initiated and the patient improved. At four years of age she required non-invasive ventilation during sleep and had no other systemic problems. The c.42C > T (p.Tyr14*) variant was reported in a patient who presented with LO-CCHS at 5 weeks of age without HSCR or PNTs (Trochet et al., 2009 Here, we report a term infant with a novel NPARM, c.13G > T (p. Glu5*), who presented with cyanosis and hypoventilation at birth, and a ten year old child with c.18T > C (p.Tyr6*). Neither had detectable HSCR or PNTs or required waking ventilator support via tracheostomy, although both needed assisted ventilation during sleep. We found that the p.Glu5*, p.Tyr6*, and p.Tyr8* variants produce N-terminally truncated proteins that localize to the nucleus and activate the DBH target promoter similar to p.Tyr14*. These data suggest a genotype-phenotype correlation between nonsense variants in exon 1 of PHOX2B and CCHS, and that the location of nonsense variants within the gene should be taken into consideration when managing patients with this disorder. 
| Plasmid generation
Human PHOX2B (NM_003924.3), with a C-terminal Myc tag was synthesized using the GeneArt Gene Synthesis service (ThermoFisher Scientific). The PHOX2B mutants were generated from the wild-type template by PCR using forward primers containing the mutation and the In-Fusion Cloning kit (Clontech). The DBH luciferase reporter construct was a kind gift from Dr. Kuixing Zhang. 
| Western blots
Cell Lysates were collected in 200 μl of Laemmli Buffer (BioRad), heated to 98°C for 5 min, and sonicated. A 10 μl of lysate was ran on precast gradient gels, 4-20% (Mini-PROTEAN® TGX™, BioI-Rad), and then transferred to a nitrocellulose membrane using the BioRad Turbo Transfer System. Primary antibody incubation was performed with rabbit anti-myc antbodies (ab9106; Abcam) or mouse anti-tubulin (T9026; Sigma), followed by a secondary antibody incubation using goat-anti-rabbit-HRP antibodies (G21234; Life Technologies) or antimouse-HRP antibodies (F21453; Life Technologies). Bands were then visualized with Luminata Forte Western HRP substrate (Millipore) and imaged using UVP-gel documentation system.
| Immunofluorescence
Cells transfected with the Phox2B constructs were fixed in 3% (wt/vol) paraformaldehyde/phosphate buffered saline (PBS) for 10 min followed by permeablization using 0.4% (wt/vol) Triton X-100/PBS for 15 min. Expressed Phox2B was labeled with rabbit polyclonal anti-myc (ab9106; Abcam) followed by a secondary antibody incubation using Alexa-Fluor 488 conjugated goat anti-rabbit (Life Technologies). DNA was detected with Hoechst dye 33258. Coverslips were mounted using 10% (wt/vol) Mowiol 4-88 (Polysciences). Images were obtained using Nikon Ni-E microscope (40x/0.75 Plan Fluor; Nikon) with a CCD camera (CoolSNAP Myo; Photometrics) linked to a workstation running NES-Element software (Nikon) was used.
4 | RESULTS 4.1 | PHOX2B nonsense variants in exon 1 produce N-terminally truncated proteins Trochet et al. (2009) showed that the PHOX2B p.Tyr14* variant leads to an N-terminally truncated protein through translational reinitiation at either p.Met18 or p.Met21. Given their close proximity within the gene and similar clinical presentation, we hypothesized that the p. Glu5* and p.Tyr6* variants detected in our patients and the previously published p.Tyr8* also produce an N-terminally truncated PHOX2B protein (Figure 1 ). Mutant and wild-type myc-tagged cDNA constructs were expressed in HeLa cells, since they do not express endogenous PHOX2B. Immunoblot analysis using anti-myc antibodies demonstrated that p.Glu5*, p.Tyr6*, and p.Tyr8* constructs all expressed a truncated protein with similar size as the previously reported p.Tyr14* mutant (Figure 2) . Interestingly, the wild-type construct also expressed a minor band at the same size as the truncated proteins and the p.Tyr8* construct expressed a minor band at the same size as wild-type.
To determine if p.Met18 or p.Met21 was the secondary ATG start site, the overexpressed proteins were isolated, digested with trypsin to cleave into smaller fragments and analyzed by mass spectrometry. An N-terminal peptide containing either start site was not detected (data not shown). Additional studies are required to determine which methionine is the true novel start site.
| PHOX2B N-terminally truncated proteins localize to the nucleus
As a transcription factor, PHOX2B localization is almost exclusively nuclear. Studies have shown that expansion of the polyalanine repeat region causes protein aggregation and mislocalization to the cytoplasm (Bachetti et al., 2005; Trochet et al., 2005) . The p.Lys155* variant produces a C-terminally truncated protein that shows substantially decreased, but not completely abolished, nuclear localization. In contrast, the p.Tyr14* pathogenic variant has normal nuclear localization (Trochet et al., 2009) . To determine if the p.Glu5*, p.Tyr6*, and p. Tyr8* variants encoded proteins localizing to the nucleus, we overexpressed cDNAs containing these alleles as well as the wild-type and p. 
| PHOX2B N-terminally truncated proteins transactivate a target promoter
Polyalanine expansions in PHOX2B result in a marked reduction in the ability of the protein to activate target gene promoters, such as DBH, PHOX2A, and TLX2 (Adachi, Browne, & Lewis, 2000; Di Lascio et al., 2013) . However, the truncated protein produced by the p.Tyr14* variant dimerizes like wild-type and transactivates the PHXO2A and DBH promoters (Trochet et al., 2009) . We therefore tested the ability of the additional variants to activate the DBH target promoter.
Transactivation by all variants was similar to the wild-type protein FIGURE 1 Location of nonsense pathogenic variants within PHOX2B. To date, five nonsense variants have been reported in PHOX2B. The p.Lys155* variant is predicted to lead to a C-terminally truncated protein, and was reported in a patient with CCHS, HSCR and neuroblastoma. In contrast, the other four nonsense variants are located in the first exon of PHOX2B and have been reported in patients who do not require daytime ventilation. HSCR and PNTs have not been reported in these patients [Color figure can be viewed at wileyonlinelibrary.com] Tyr3*) variant is expected to cause a severe Duchenne muscular dystrophy (DMD); however, the clinical presentation is that of the milder Becker muscular dystrophy (Gurvich et al., 2009 ). Immunoblot analysis of dystrophin detected a protein of reduced size consistent with translational reinitiation within exon 6. In contrast, the c.355C > T (p.Gln199*) variant in exon 5 associates with a DMD phenotype, and thus highlights that not every PT variant upstream from a putative translational reinitiation site functions similarly.
Often mRNAs encoding PT variants are degraded through nonsense-mediated decay (NMD), a post-transcriptional surveillance mechanism. This mechanism prevents synthesis of truncated proteins with potentially toxic effects. Transcripts with PT variants near the AUG start codon can escape NMD through juxtaposition of the PABPC1 protein to the mutation through mRNA circularization (Inacio et al., 2004; Silva, Ribeiro, Inacio, Liebhaber, & Romao, 2008) , the "AUG-proximity effect," and through the capacity to reinitiate translation at a downstream in-frame methionine (Neu-Yilik et al., 2011) . Consequently, only some transcripts with PT variants close to the AUG start site will be degraded by NMD and evaluation must be performed on a gene-by-gene and mutation-by-mutation basis.
The variable activation of NMD versus reinitiation of translation likely contributes to phenotypic heterogeneity associated with proximal premature termination mutations. PHOX2B forms homodimers through the homeobox domain, and in vitro also forms heterodimers with its paralogue PHOX2A.
Expansion of the polyalanine track impairs dimerization by altering protein folding, leading to aggregation in the cytosol, and impeding nuclear import (Bachetti et al., 2005; Di Lascio et al., 2013; Di Lascio, Belperio, Benfante, & Fornasari, 2016; Trochet et al., 2005) .
Consequently, even if the PHOX2B protein with expansion of the polyalanine track can escape cytosolic aggregation and move into the nucleus, its poor dimerization impedes transactivation of target promoters (Bachetti et al., 2005; Cargnin et al., 2005; Trochet et al., 2005) . These observations suggest that PHOX2B proteins with expansions of the polyalanine track have antimorphic and neomorphic properties, as well as loss of original function.
Consistent with this, mice with PHOX2B polyalanine track expansions have a different phenotype than those with a loss of the whole gene. Mice heterozygous for a +7 alanine expansion resemble a severe presentation of CCHS and die of respiratory failure in the first hours (Goridis, Dubreuil, Thoby-Brisson, Fortin, & Brunet, 2010) . In contrast, heterozygous PHOX2B knockout mice are viable and fertile, and have no detectable differences in apnea and ventilation during waking compared to wild-type mice (Durand et al., 2005) , although they have an altered response to hypoxia and hypercarbia and disordered breathing and longer apnea events during sleep (Dauger et al., 2003; Durand et al., 2005) . It is difficult to compare the knockout mouse model to humans with CCHS, since only three patients with genomic deletions encompassing the whole PHOX2B have been reported and those deletions encompass additional genes (Jennings et al., 2012) . The identification of additional human deletions of PHOX2B will eventually clarify this.
In the cases in which translational reinitiation occurs, a PHOX2B protein presumably missing the first 18-21 amino acids appears to have normal nuclear localization, dimerization, DNA binding, and target promoter activation. When the clinical presentation is taken into account, it appears that the truncated protein is more likely to represent a haploinsufficiency model, similar to a whole gene deletion. Since PHOX2B regulates its own expression by an autoregulatory method and binds to multiple sites in its promoter region (Cargnin et al., 2005) , it is possible that a threshold is required to reach full expression. Thus, reduction by either loss of the entire gene or a requisite function leads to a decrease in PHOX2B expression.
In conclusion, we have shown that four different nonsense 
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